Cytokine-Induced Killer (CIK) Cells, In Vitro Expanded under Good Manufacturing Process (GMP) Conditions, Remain Stable over Time after Cryopreservation [PDF]
Pharmaceuticals, 2020 Cytokine-induced killer (CIK) cells are advanced therapy medicinal products, so their production and freezing process has to be validated before their clinical use, to verify their stability as a drug formulation according to the good manufacturing ...
Katia Mareschi +10 more
doaj +6 more sources
Innovative Clinical Perspectives for CIK Cells in Cancer Patients. [PDF]
Int J Mol Sci, 2018 Cytokine-induced killer (CIK) cells are T lymphocytes that have acquired, in vitro, following extensive manipulation by Interferon gamma (IFN-γ), OKT3 and Interleukin 2 (IL-2) addition, the expression of several Natural Killer (NK) cell-surface markers.
Introna M, Correnti F.
europepmc +6 more sources
Anti-CD40 predominates over anti-CTLA-4 to provide enhanced antitumor response of DC-CIK cells in renal cell carcinoma [PDF]
Frontiers in Immunology, 2022 Cytokine-induced killer cells (CIK) in combination with dendritic cells (DCs) have shown favorable outcomes in renal cell carcinoma (RCC), yet some patients exhibit recurrence or no response to this therapy.
Ying Zhang +7 more
doaj +4 more sources
CD44v6 as innovative sarcoma target for CAR-redirected CIK cells. [PDF]
Oncoimmunology, 2018 Purpose of our study was to explore a new immunotherapy for high grade soft tissue sarcomas (STS) based on cytokine-induced killer cells (CIK) redirected with a chimeric antigen receptor (CAR) against the tumor-promoting antigen CD44v6. We aimed at generating bipotential killers, combining the CAR specificity with the intrinsic tumor-killing ability of
Leuci V +15 more
europepmc +10 more sources
Improving Clinical Manufacturing of IL-15 Activated Cytokine-Induced Killer (CIK) Cells [PDF]
Frontiers in Immunology, 2019 Cytokine-induced killer (CIK) cells are an immunotherapeutic approach to combat relapse following allogeneic hematopoietic stem cell transplantation (HSCT) in acute leukemia or myelodysplastic syndrome (MDS) patients. Prompt and sequential administration
Melanie Bremm +13 more
doaj +4 more sources
Preclinical evaluation of DC-CIK cells as potentially effective immunotherapy model for the treatment of glioblastoma [PDF]
Scientific ReportsDespite the favorable effects of immunotherapies in multiple types of cancers, its complete success in CNS malignancies remains challenging. Recently, a successful clinical trial of cytokine-induced killer (CIK) cell immunotherapy in patients with ...
Annika Simone Lück +6 more
doaj +2 more sources
An Exploratory in vitro Study of Cytotoxicity and Cytokine Profiling of Cytokine-Induced Killer (CIK) Cells Against HCT-15 Colorectal Cancer (CRC) Cells [PDF]
ImmunoTargets and TherapySze-Piaw Chin,1,2 Natasha Najwa Nor Arfuzir,1 Vivian Wai-Ping Kong,3 Soon-Keng Cheong1,2 1Department of Research and Development, Cytopeutics Sdn Bhd, Cyberjaya, Selangor, Malaysia; 2M.
Chin SP +3 more
doaj +2 more sources
Frontiers in ImmunologyIntroductionCAR-T cell therapy, though successful in hematologic malignancies, faces challenges in solid tumors due to limitations of autologous T cells.
Laura M. Moser +51 more
doaj +3 more sources
PLoS ONE, 2023 Background Cytokine-induced killer (CIK) cells are heterogeneous lymphocytes from human peripheral blood mononucleated cells (PBMCs) co-cultured with several cytokines.
Chan-Keng Yang +6 more
doaj +2 more sources
Frontiers in Immunology, 2021 Cytokine-induced killer (CIK) cells are an ex vivo expanded heterogeneous cell population with an enriched NK-T phenotype (CD3+CD56+). Due to the convenient and relatively inexpensive expansion capability, together with low incidence of graft versus host
Xiaolong Wu +7 more
doaj +1 more source